- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cancer and Blood Specialists of NOVA Has Joined the American Oncology Network
American Oncology Network, LLC (AON) is pleased to announce that Cancer and Blood Specialists of NOVA, a leading community oncology and hematology practice serving Northern Virginia, has joined AON.
Fort Myers, Fla., May 4, 2020—American Oncology Network, LLC (AON) is pleased to announce that Cancer and Blood Specialists of NOVA, a leading community oncology and hematology practice serving Northern Virginia, has joined AON, effective May 1, 2020.
Cancer and Blood Specialists of NOVA has been providing comprehensive, state-of-the-art treatment for patients diagnosed with cancer and blood disorders at its clinic in the Washington D.C. Metropolitan area since 1987. The practice was founded by Medical Oncologist and Hematologist Dr. Masoom Kandahari. Dr. Kandahari is currently joined by Medical Oncologist and Hematologist Dr. Farn Chan and a nurse practitioner.
“We are excited to have Drs. Kandahari and Chan join AON,” said AON CEO Brad Prechtl, MBA. “Cancer and Blood Specialists of NOVA will continue to offer the highest level of cancer care with enhanced services such as home delivery for oral oncolytic medications and centralized laboratory and pathology services for quicker results.”
“This partnership with AON and the Cancer and Blood Specialists of NOVA will help drive change in community cancer care with access to advanced technologies and the latest treatment options for Virginia patients,” said AON Board Member & Chairman Dr. Stephen Orman.
Read the full press release here.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
